✦ LIBER ✦

A 24-WEEK STUDY OF ALIROCUMAB AS MONOTHERAPY VERSUS EZETIMIBE: THE FIRST PHASE 3 DATA OF A PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 INHIBITOR

✍ Scribed by Roth, Eli M.; Taskinen, Marja-Riitta; Ginsberg, Henry; Kastelein, John; Colhoun, Helen M.; Merlet, Laurence; Pordy, Robert; Baccara-Dinet, Marie T.

Book ID: 122187272
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 180 KB
Volume: 63
Category: Article
ISSN: 1558-3597
DOI: 10.1016/S0735-1097(14)61370-X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Monotherapy with the PCSK9 inhibitor ali

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24week, double-blind, randomized Phase 3 trial

✍ Roth, Eli M.; Taskinen, Marja-Riitta; Ginsberg, Henry N.; Kastelein, John J.P.; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 586 KB

Efficacy, safety, and tolerability of a

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study

✍ Michael J Koren; Rob Scott; Jae B Kim; Beat Knusel; Thomas Liu; Lei Lei; Michael 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 384 KB

RANDOMIZED, PARTIAL BLIND STUDY OF THE P

RANDOMIZED, PARTIAL BLIND STUDY OF THE PHARMACODYNAMICS, PHARMACOKINETICS AND SAFETY OF MULTIPLE SUBCUTANEOUS DOSES OF ALIROCUMAB, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9, ADMINISTERED EVERY 4 WEEKS ALONE OR IN COMBINATION WITH EZETIMIBE OR FENOFIBRATE IN HEALTHY SUBJECTS

✍ Rey, Jacques; Poitiers, Franck; Paehler, Tobias; Brunet, Aurelie; Pinquier, Jean 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 180 KB